Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 2/20 | 0.39 |
| ▸ | RET | P07949 | 1/20 | 0.39 |
| ▸ | HTR2C | P28335 | 1/20 | 0.39 |
| ▸ | HTR2B | P41595 | 1/20 | 0.39 |
| ▸ | OPRL1 | P41146 | 3/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.38 |
| ▸ | FNTA | P49354 | 1/20 | 0.37 |
| ▸ | FNTB | P49356 | 1/20 | 0.37 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.37 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.37 |
| ▸ | ACP3 | P15309 | 1/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22193900 | 1.00 | HTR2A (0.39) | HTR2ARETHTR2CHTR2BOPRL1 | |
| SCHEMBL13611706 | 0.81 | FNTA (0.58) | FNTAFNTB | |
| SCHEMBL4969358 | 0.80 | FNTA (0.41) | HTR2ARETOPRL1KCNH2FNTA | |
| SCHEMBL12050758 | 0.79 | P2RX7 (0.41) | HTR2ARETOPRL1KCNH2FNTA | |
| SCHEMBL22193783 | 0.79 | RET (0.39) | HTR2ARETOPRL1KCNH2FNTA | |
| SCHEMBL6992704 | 0.78 | PDPK1 (0.45) | HTR2ARETOPRL1KCNH2FNTA | |
| SCHEMBL16559194 | 0.78 | FNTA (0.38) | HTR2ARETOPRL1KCNH2FNTA | |
| SCHEMBL8746509 | 0.78 | HTR2A (0.52) | HTR2ARETHTR2CHTR2BKCNH2 | |
| SCHEMBL24631673 | 0.77 | HTR2A (0.46) | HTR2ARETHTR2COPRL1KCNH2 | |
| SCHEMBL6992701 | 0.75 | HTR2A (0.66) | HTR2ARETHTR2CCYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160228438-A1 | AZA-PYRIDONE COMPOUNDS AND USES THEREOF | ALIOS BIOPHARMA, INC. | 2016-08-11 | — | — | US | disclosed |
| US-9328119-B2 | AZA-pyridone compounds and uses thereof | ALIOS BIOPHARMA, INC. (US) | 2016-05-03 | — | — | US | disclosed |
| US-20150072982-A1 | AZA-PYRIDONE COMPOUNDS AND USES THEREOF | Janssen Pharmaceuticals, Inc. | 2015-03-12 | — | — | US | disclosed |
| US-7598242-B2 | Compounds for the treatment of inflammatory disorders | SCHERING CORPORATION (US) | 2009-10-06 | — | — | US | disclosed |
| US-7598242-B2 | Compounds for the treatment of inflammatory disorders | SCHERING CORPORATION (US) | 2009-10-06 | — | — | US | disclosed |
| WO-2003053915-A2 | COMPOUNDS FOR THE TREATMENT OF INFLAMMATORY DISORDERS | SCHERING CORPORATION (US) | 2003-07-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160228438-A1 | AZA-PYRIDONE COMPOUNDS AND USES THEREOF | PNPO, ITPA, PDXK | HTR2A 2424/4885RET 2470/4885HTR2C 2595/4885 |
| US-20150072982-A1 | AZA-PYRIDONE COMPOUNDS AND USES THEREOF | PNPO, ITPA, PDXK | HTR2A 2424/4885RET 2470/4885HTR2C 2595/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.